Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.88 USD | +0.61% | -2.23% | -25.15% |
Sales 2024 * | 11.88M 14.84M | Sales 2025 * | 88.56M 111M | Capitalization | 965M 1.21B |
---|---|---|---|---|---|
Net income 2024 * | -87M -109M | Net income 2025 * | -49M -61.23M | EV / Sales 2024 * | 65.7 x |
Net cash position 2024 * | 184M 230M | Net cash position 2025 * | 146M 183M | EV / Sales 2025 * | 9.24 x |
P/E ratio 2024 * |
-23.9
x | P/E ratio 2025 * |
-44.4
x | Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +0.61% | ||
1 week | -2.23% | ||
Current month | -3.69% | ||
1 month | -11.85% | ||
3 months | -8.60% | ||
6 months | +5.46% | ||
Current year | -25.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 14.88 | +0.61% | 422,783 |
24-05-07 | 14.79 | -1.07% | 328,543 |
24-05-06 | 14.95 | -4.72% | 601,004 |
24-05-03 | 15.69 | -0.38% | 507,486 |
24-05-02 | 15.75 | +3.48% | 689,321 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.15% | 1.2B | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- VRNA Stock